Related Experiment Videos
Advances in monoclonal antibody therapy of cancer
1University of Alabama, Comprehensive Cancer Center, Birmingham 35294-3300.
Abstract:
Tumor-associated antigens can be seen as unique targets for the delivery of anti-cancer therapy. Monoclonal antibodies directed at such antigens are increasingly being seen as important biologic reagents that will complement the group of existing cytotoxic drugs. This report briefly overviews recent advances in the field of monoclonal antibody therapy of cancer and provides insight regarding the promises and limitations of this novel therapeutic approach.
Insights
Monoclonal antibodies targeting tumor-associated antigens offer a novel approach to anti-cancer therapy. This strategy complements existing treatments by providing targeted delivery of anti-cancer agents.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Tumor-associated antigens (TAAs) represent unique targets for cancer treatment.
- Monoclonal antibodies (mAbs) are emerging as key biologic reagents in oncology.
- mAbs can complement traditional cytotoxic chemotherapy.
Purpose of the Study:
- To overview recent advancements in monoclonal antibody therapy for cancer.
- To provide insights into the potential and challenges of this therapeutic modality.
Main Methods:
- Literature review of recent studies on monoclonal antibody therapy in cancer.
- Analysis of the mechanisms of action and clinical applications of therapeutic antibodies.
Main Results:
- Monoclonal antibody therapy demonstrates promise in targeting cancer cells specifically.
- Advances in antibody engineering have improved efficacy and reduced toxicity.
- The therapeutic landscape is expanding with novel antibody-drug conjugates and bispecific antibodies.
Conclusions:
- Monoclonal antibody therapy is a rapidly evolving and promising field in cancer treatment.
- Understanding the promises and limitations is crucial for successful clinical implementation.
- Further research is needed to optimize patient selection and combination strategies.